“My cough was really so deep that it felt like I broke my ribs, and my ribs became so cramped that I couldn’t even twist [my body].”

Voice of the Patient Report: “Idiopathic Pulmonary Fibrosis”, March 2015.

“My cough was really so deep that it felt like I broke my ribs, and my ribs became so cramped that I couldn’t even twist [my body].”

Voice of the Patient Report: “Idiopathic Pulmonary Fibrosis”, March 2015.

Haduvio and Chronic Cough

Chronic cough impacts up to 10% of the adult population and has physical, psychological, and social impacts on patients’ lives. There are currently no approved therapies in the U.S. or U.K. It is highly disruptive and accompanied by a wide range of complications, which causes a significant burden on patients, caregivers, and healthcare systems. The cause of chronic cough is believed to be the result of a hypersensitivity disorder in the central and peripheral nerves.

Haduvio’s unique mechanism of action (MOA) across both the central and peripheral nervous systems, has the potential to rebalance the receptors for a synergistic effect to treat chronic cough. Haduvio reduced daytime cough frequency by 75% in idiopathic pulmonary fibrosis (IPF) subjects in its Phase 2 Cough And NALbuphine trial. The safety results of the CANAL trial were generally consistent with the known safety profile of Haduvio from previous trials. To build upon this positive data, we are advancing future clinical development on chronic cough conditions, including IPF and refractory chronic cough (RCC).